Filament Health Corp. (FLHLF)
| Previous Close | 0.0344 |
| Open | 0.0344 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0344 - 0.0369 |
| 52 Week Range | 0.0320 - 0.2010 |
| Volume | |
| Avg. Volume | 17,935 |
| Market Cap | 7.794M |
| Beta (5Y Monthly) | 1.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
CNW GroupFILAMENT HEALTH TO DISCUSS ITS DRUG DEVELOPMENT PLATFORM IN FIRESIDE CHAT WITH WATER TOWER RESEARCH ON APRIL 4, 2024 AT 12PM ET
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, will be participating in the Water Tower Research Fireside Chat Series on April 4, 2024, at 12:00 pm ET.
CNW GroupFILAMENT HEALTH REPORTS Q4 AND YEAR END 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its fourth quarter financial results and operational highlights for the period ended December 31, 2023.
CNW GroupFILAMENT HEALTH ANNOUNCES APPOINTMENT OF MICHAEL MESSINGER TO ITS BOARD OF DIRECTORS
Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced the appointment of Michael Messinger, CPA, to its Board of Directors (the "Board"). Mr. Messinger will also serve as the Chair of the Company's Audit Committee.
